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Abstract
Objective To investigate 1-year outcomes with routine prasugrel treatment after acute coronary syndrome (ACS) in
a large-scale registry.
Methods The Rijnmond Collective Cardiology Research registry is a prospective, observational study that enrolled
4,258 consecutive ACS patients treated with percutaneous coronary intervention (PCI) with 1-year follow-up. Patients
received prasugrel as first-choice antiplatelet agent, except for increased bleeding risk patients in which clopidogrel was
recommended. Events were validated by an independent clinical endpoint committee.
Results A total number of 2,677 patients received prasugrel at discharge after the index event. Eighty-one percent of the
target population was on prasugrel treatment at hospital discharge. At 1 year, the primary endpoint, a composite of all-cause
mortality and myocardial infarction, occurred in 2.4% of patients receiving prasugrel. All-cause mortality occurred in 1.0%,
myocardial infarction in 1.5%, target-vessel revascularisation in 3.1%, stent thrombosis in 0.6%, and stroke in 0.5% of
the patients treated with prasugrel. Thrombolysis in Myocardial Infarction defined major bleeding episodes not related to
coronary artery bypass grafting were observed in 1.4% of patients receiving prasugrel.
Conclusions In routine practice, a tailored approach of prasugrel prescription in ACS patients undergoing PCI, resulted
in low ischaemic and low bleeding rates up to 1 year post PCI.
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What’s new?
● Real-world data with current potent antiplatelet therapies
is limited to low frequency use.
● A single antiplatelet therapy protocol was successfully
implemented in 8 non-PCI-capable and 3 PCI-capable
collaborating hospitals for all ACS patients.
● This resulted in a high penetration of current potent an-
tiplatelet therapies with a low prescription rate for non-
recommended or contra-indicated patients
● Within the high frequency use real-world data population
no excess major bleeding events were observed.
Introduction
Current European and North-American guidelines provide
a Class I recommendation for the administration of dual
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antiplatelet therapy to patients presenting with acute coro-
nary syndrome (ACS) who are undergoing percutaneous
coronary intervention (PCI), consisting of aspirin to in-
hibit platelet thromboxane production and one of the newer
P2Y12 receptor antagonists, such as prasugrel, to prevent
secondary platelet activation [1, 2]. This recommendation
was introduced following large classic randomised trials [3,
4].
As with every novel pharmacological principle, docu-
mentation of real-life contemporary results is of utmost
importance, especially when considering that baseline and
procedural characteristics in clinical trial participants dif-
fer considerably from those in non-participants along with
a better survival observed in trial participants [5]. In this
sense longitudinal clinical registries that provide informa-
tion on the effectiveness and safety in real-world patient
populations are of utmost importance. Accordingly, our
aim was to study the introduction of prasugrel into con-
temporary practice to understand the appropriateness of its
use. Hence, we aimed to observe treatment patterns and
1-year outcomes associated with routine prasugrel treat-
ment using a tailored strategy in PCI-treated ACS patients
in the large-scale prospective Rijnmond Collective Cardiol-
ogy Research (CCR) study.
Methods
Study design and population
Full details of the CCR study rationale and methodology
(Dutch Trial Register identifier: NTR3704) have been re-
ported elsewhere [6]. In brief, the CCR study was a prospec-
tive, multicentre, observational registry of management
practices and outcome of ACS up to 12 months post-
discharge involving three high-volume centres with PCI
capability and eight non-PCI centres in the Rijnmond re-
gion in the Netherlands (Appendix A). The CCR study was
initiated in August 2011, after the Guideline Committee of
the participating network updated the treatment guidelines
to include prasugrel as the first-line treatment option for
antiplatelet therapy in PCI patients. A maintenance dose
of 10mg prasugrel was preferred, while a maintenance
dose of 75mg clopidogrel was recommended for patients
with prior stroke or transient ischaemic attack (TIA) and
5mg prasugrel for patients over 75 years or weighing less
than 60kg following the European label for prasugrel where
75mg clopidogrel served as an alternative when 5mg prasu-
grel was not available. To avoid the off-label use of prasu-
grel, clopidogrel was recommended in patients with a high
clinical bleeding risk. We completed the enrolment in June
2013. No treatment intervention was directed by protocol in
the CCR study. Therefore, the treating physicians made all
treatment decisions in accordance with practice guideline
recommendations and local standards of care and practice.
Patients were not subjected to special treatments or di-
agnostic test or imposed to any mode of behaviour for the
purpose of this study, other than standard treatment. There-
fore, according to Dutch law, we did not require written
informed consent for a patient to be enrolled in this study.
This study was conducted according to the Privacy Policy
of the Erasmus MC and according to the Erasmus MC reg-
ulations for the appropriate use of data in patient-oriented
research. It was also approved by the regional ethics com-
mittee.
Data collection and event validation
Patient characteristics, clinical features, angiographic and
procedural details, and in-hospital outcomes were ab-
stracted from the medical chart per routine and entered
into a secure web-based centralised database. After the
index hospitalisation, patients were routinely followed up
at 1 month and 12 months at the outpatient clinics of the
enrolling sites where medication adherence was checked.
Dedicated study staff visited the individual sites for mon-
itoring and all events were validated by an independent
clinical endpoint committee [6].
Study endpoints
The primary endpoint for the current study was the com-
posite of all-cause mortality and non-fatal myocardial in-
farction (MI) for hospital survivors discharged on long-
term prasugrel therapy. Secondary efficacy endpoints in-
cluded the composite of cardiovascular death, non-fatal MI
and target vessel revascularisation defined as major adverse
cardiac events (MACE), stroke, stent thrombosis (ST) ac-
cording to definite or probable Academic Research Con-
sortium definitions [7], and all individual components of
the composite endpoints, as previously defined [6]. Safety
endpoints included thrombolysis in myocardial infarction
(TIMI) major and minor bleeding events that were unre-
lated to coronary artery bypass grafting (CABG) after index
PCI, as defined per TRITON-TIMI 38 criteria [4].
Statistical analysis
Continuous variables are summarised as mean± standard
deviation (SD) or median with interquartile range (IQR),
depending on the distribution pattern. We compared the
continuous variables using the Student’s t-test (normal dis-
tribution) or Mann-Whitney U-test (non-normal distribu-
tion) as appropriate. Categorical variables are summarised
as frequencies and percentages and were compared using
the chi-square test. Clinical outcomes are presented as the
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Fig. 1 Study flow chart
Enrolled patients
(N = 4258)
In-hospital deaths
(N = 121)
Hospital survivors
(N =4137)
Clopidogrel at discharge
(N = 1420)
No P2Y12 inhibition at 
discharge
(N = 40)
Prasugrel at discharge
(N = 2677; guideline 
adherence rate 81%)
cumulative incidence based on the Kaplan-Meier method
(%). Patients lost to follow-up were considered at risk until
the date of last contact, at which time point they were cen-
sored. Statistical tests were two-sided and a p-value< 0.05
was considered statistically significant. Computations were
performed using SAS version 9.2 (SAS Institute, Cary, NC,
USA).
Results
Demographic characteristics
During the enrolment period a number of 4,258 consec-
utive ACS patients underwent PCI according to the PCI
databases of the 3 referral centres and were enrolled in the
regional registry (Fig. 1). Demographic and clinical char-
acteristics of the total cohort are listed in Tab. 1. During
initial hospitalisation, 121 patients died and were not part
of the study cohort. Characteristics of these patients are de-
scribed in the online supplementary Tab. X1, with a high
frequency of ST-elevation myocardial infarction (STEMI)
presentation followed by either ongoing cardiogenic shock
or severe neurological damage after out-of-hospital cardiac
arrest. Of the hospital survivors 27.2% (n= 1,124) had at
least one characteristic of increased bleeding risk and an
additional 183 patients were on vitamin K antagonists (de-
tails in the online supplementary Tab. X2). Therefore, the
potential prasugrel cohort was reduced to 2,830 patients
of whom 2,282 were on target therapy at discharge (81%)
(Fig. 1). As 395 patients of the increased risk group were
still treated with 5 or 10mg prasugrel, the total study co-
hort comprised 2,677 patients, 65% of all patients (Fig. 1).
Demographic and clinical characteristics are also listed in
Tab. 1 and procedural details of the study cohort are listed
in Tab. 2. Patients discharged on prasugrel were younger
and had less clinical comorbidities compared with patients
discharged on clopidogrel. The median age of the study
cohort was 60.0 years, 23% were female and 14% had dia-
betes. Patients≥75 years of age or weighing <60kg, com-
prising subgroups in whom cautionary use of prasugrel is
advised, totalled 7.8 and 2.9% of the study cohort, respec-
tively. Prasugrel prescription in patients with prior stroke or
TIA was very low (n= 25, <1%). Half of the study cohort
(50%) presented with STEMI, 35% with non-ST-elevation
myocardial infarction (NSTEMI), and 15% with unstable
angina. In 56.2% of the population radial access was pre-
ferred.
Pharmacological treatment
The discharge prescription rates and medication use at fol-
low-up in the study cohort are listed in the online supple-
mentary Tab. X3. A prasugrel maintenance dose of 10mg
was instituted in 93.3% of patients at discharge, whereas
6.7% of patients received a maintenance dose of 5mg,
which declined to 5.4% at 1-year follow-up. The prescrip-
tion rates of a maintenance dose of 10mg prasugrel at dis-
charge in patients≥ 75 years of age or weighing <60kg
were very low (2.4%) indicating a very high adherence to
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Table 1 Demographic and clinical characteristics
All patients
(N = 4,258)
Patients receiving clopidogrel
at discharge
(N = 1,420)
Patients receiving pra-
sugrel at discharge
(N = 2,677)
Demographics
Age, year 64 (54, 73) 73 (62, 79) 60 (52, 68)
Age≥75 21.5 45.1 7.8
Woman 27.5 35.7 23.0
Weight, kg 80 (73, 91) 80 (70, 90) 82 (74, 93)
Weight <60kg 4.0 5.9 2.9
Cardiovascular risk factors
Diabetes mellitus 17.0 21.5 14.0
Hypertension 51.6 61.9 45.6
Hypercholesterolaemia 37.6 41.9 35.1
Current smoking 36.0 21.9 43.6
Family history of CAD 44.3 39.5 47.6
Cardiovascular disease history
MI 18.3 24.5 15.0
PCI 18.0 25.1 14.4
CABG 5.6 10.3 3.2
Stroke or TIA 7.3 18.4 0.9
Peripheral artery disease 7.2 10.7 4.8
Congestive heart failure 3.8 5.6 2.7
Laboratory findings
Creatinine, µmol/l 80 (69, 95) 83 (70, 101) 78 (68, 91)
Haemoglobin, mmol/l 8.9 (8.2, 9.5) 8.7 (7.9, 9.3) 9.0 (8.4, 9.6)
Thrombocytes, 109/l 234 (195, 277) 233 (194, 277) 234 (196, 278)
Positive (>13ng/l) high-sensitivity troponin test
during admission
85.4 79.8 87.9
Presentation
Admission diagnosis
– Unstable angina 19.4 28.4 15.2
– NSTEMI 36.9 43.3 34.6
– STEMI 43.8 28.3 50.1
Left ventricular functiona
– Normal (≥50%) 66.1 63.2 68.2
– Moderate (30–49%) 29.4 30.5 28.7
– Poor (<30%) 4.5 6.3 3.1
Continuous data are presented as median (25th, 75th percentile), and categorical data are presented as percentages. All differences in
characteristics between patients receiving clopidogrel at discharge and those receiving prasugrel at discharge were statistically significant
(p< 0.001), except median thrombocytes (p= 0.36)
CABG coronary artery bypass grafting; CAD coronary artery disease; IQR interquartile range; MI myocardial infarction; NSTEMI
non-ST-elevation myocardial infarction; PCI percutaneous coronary intervention; SD standard deviation; STEMI ST-elevation myocardial
infarction; TIA transient ischaemic attack
aAvailable in 2,920 patients
the regional protocol. Triple antithrombotic therapy with
aspirin, prasugrel and a vitamin K antagonist was instituted
in 3.3% of patients at discharge and declined to 1.8% at
1-year follow-up.
Outcomes
Clinical follow-up was available for 2,615 patients (97.7%)
at one month and 2,443 patients (91.3%) at one year. Of
note, all patients lost to follow-up for nonfatal endpoints
were reported alive by municipal civil registries. The effi-
cacy and safety endpoints at one month and one year are
presented in Tab. 3. The primary combined endpoint of all-
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Table 2 Treatments and procedures in patients receiving prasugrel at
discharge
Timings and durations N = 2,677
Admission to PCI, days (by diagnosis)
– Unstable angina 2.0 (0, 4.0)
– NSTEMI 1.0 (0, 4.0)
– STEMI 0 (0, 0)
Admission duration, days 4.0 (3.0, 6.0)
Procedural characteristics
Access site
– Femoral 39.1
– Radial 56.2
– Other 4.7
Treated vessel
– Right coronary artery 37.1
– Left main 2.5
– Left anterior descending 46.8
– Left circumflex 25.2
– Arterial or saphenous grafts 1.3
Multivessel PCI during index procedure 13.5
Periprocedural antithrombotic treatment
Aspirin 88.3
Clopidogrel 12.6
Prasugrel 78.5
Clopidogrel and prasugrel 0.7
Glycoprotein IIb/IIIa inhibitor 17.0
Unfractionated heparina 100
Low-molecular-weight heparin 2.7
Continuous data are presented as median (25th, 75th percentile), and
categorical data are presented as percentages
NSTEMI non-ST-elevation myocardial infarction; PCI percutaneous
coronary intervention; STEMI ST-elevation myocardial infarction
aWe did not record heparin use in individual patients, but heparin is
used during PCI procedures in patients with acute coronary syndrome
as per treatment protocol in the regional PCI centres
cause mortality or non-fatal MI occurred in 0.8% of patients
at one month and in 2.4% at one year. The incidence of the
individual endpoints were very low at one year, with tar-
get vessel revascularisation comprising the most frequently
observed individual endpoint with a 3.1% event rate. TIMI
major bleeding events unrelated to CABG occurred in 20
(0.8%) patients at one month and in 1.4% at one year. The
most common types of TIMI major bleeding events in the
course of one month were bleeding at vascular access sites
(n= 7; 35% of all bleeding events), gastrointestinal haem-
orrhage (n= 3), intracranial haemorrhage (n= 2) and other
(n= 8). In the course of one year, 17 additional patients ex-
perienced a TIMI major bleeding event. One-year efficacy
and safety data in selected strata are presented in the online
supplementary Tab. X4.
Discussion
In this large-scale registry, 81% of all consecutive ACS
patients treated with PCI who were eligible for a newer
and more potent guideline-recommended P2Y12 receptor
antagonist were discharged on prasugrel. These patients
exhibited low rates of ischaemic events, including overall
mortality post discharge, and low rates of major bleeding
events in routine contemporary practice. These data provide
important evidence with regard to the efficacy and safety of
real-world use of prasugrel as part of an antiplatelet strategy
with a tailored approach.
Our findings are consistent with the TRITON-TIMI
38 trial in terms of efficacy of prasugrel, with an even bet-
ter safety profile. In TRITON-TIMI 38, prasugrel reduced
the incidence of the primary endpoint of cardiovascular
death, MI, and stroke compared with clopidogrel (9.9%
vs. 12.1%; P< 0.001) in ACS patients undergoing PCI,
but it also increased the risk for non-CABG TIMI major
bleeding, particularly among the elderly (≥75 years), as
well as in those with low body weight (<60kg), prior
stroke or TIA [3]. We observed much lower rates of ef-
ficacy endpoints along with low rates of bleeding. These
results may be explained, at least in part, by the low-risk
profile of the current study population and demonstrate
the efficacy of our tailored approach in routine clinical
practice where potentially 66% of all ACS-PCI patients
were on full-dose high-effective dual antiplatelet therapy.
In fact, our results are much more in line with recent
TRITON-TIMI 38 subanalyses [8] in which the benefit of
prasugrel was maximised and the risk of adverse outcomes
limited by excluding high-risk patients. Importantly, in-
hospital deaths after the index procedure were not part of
the study cohort (N= 121) and non-fatal major bleeding
events among these patients were limited (n= 7, of which
3 on prasugrel), whereas in-hospital bleeding events in the
study cohort were still included for the analysis. In this
respect, the currently observed low mortality rate is partly
explained by our focus on hospital survivors only, whereas
hospital mortality was mainly driven by patients with out-
of-hospital cardiac arrest or patients who presented with
cardiogenic shock.
When we focus on bleeding events, we see that pra-
sugrel pretreatment significantly increased bleeding com-
plications in ACCOAST-PCI [9], although the incidence of
major bleeding was low at 30 days (1.7 and 0.66% in the
pretreatment and no-pretreatment groups, respectively). The
incidence of major bleeding at 30 days in the CCR registry
was 0.8%. This is perfectly in line with the results from the
ACCOAST-PCI study, and remarkably close to the bleed-
ing events in the no-pretreatment arm. In this regard we
should mention the higher number of radial artery access
(56%) in the CCR study versus 56% femoral approaches
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Table 3 Clinical outcomes in patients receiving prasugrel at discharge
In-hospital 1 montha 1 yearb
Composite efficacy outcomes
All-cause death or MI (primary endpoint) 13 (0.5) 22 (0.8) 64 (2.4)
Cardiovascular death, MI or TVR 23 (0.9) 41 (1.5) 119 (4.4)
Single efficacy outcomes
All-cause death – 4 (0.2) 28 (1.0)
Cardiovascular death – 4 (0.2) 17 (0.6)
MI 13 (0.5) 19 (0.7) 39 (1.5)
Stent thrombosis 5 (0.2) 12 (0.4) 16 (0.6)
– Definite 5 11 13
– Probable 0 1 1
– Possible 0 0 2
TLR 10 (0.4) 17 (0.6) 44 (1.6)
TVR 16 (0.6) 30 (1.1) 83 (3.1)
CABG 2 (0.1) 6 (0.2) 22 (0.8)
Stroke 3 (0.1) 8 (0.3) 13 (0.5)
Safety outcome
Non-CABG TIMI major bleeding 14 (0.5) 20 (0.8) 37 (1.4)
– Access site 5 7 10
– Gastrointestinal 2 3 8
– Intracranial 0 2 6
– Other 7 8 13
Data represent the number of patients with at least one of the respective outcomes at 1 month and 1 year, respectively, and the corresponding
cumulative incidence based on the Kaplan-Meier method (%)
CABG coronary artery bypass grafting; MI myocardial infarction; TIMI thrombolysis in myocardial infarction; TLR target lesion revascularisation;
TVR target vessel revascularisation
a30 days
b400 days
in the ACCOAST-PCI study [9]. A recent subanalysis of
the ACCOAST-PCI study demonstrated that pretreatment,
age, gender and procedural variables (femoral access) were
independent predictors of TIMI major or minor bleeding in
patients with NSTEMI, a finding in line with the current
results [10].
Our results extend previous observations in registries of
PCI-treated ACS patients [11, 12]. For instance, Damman
et al. demonstrated low rates of in-hospital bleeding and 30-
day mortality for prasugrel in an analysis of the SCAAR
data [11]. Our data are also in keeping with the recent large-
scale TRANSLATE-ACS registry demonstrating lower (un-
adjusted) MACE in patients receiving prasugrel (n= 3,123)
versus clopidogrel (n= 8,846) [13]. In contrast, the current
observational study was initiated after an update of the treat-
ment guidelines to include prasugrel as the first-line treat-
ment option for antiplatelet therapy. Based on the strategy
in our study, 65% of patients were discharged on prasugrel
versus 26% in the TRANSLATE-ACS registry. With the
current strategy we were also able to limit inappropriate or
non-recommended use of prasugrel in contrast to another
national registry [14].
In the current registry, 33% of patients were discharged
on clopidogrel. To a large extent, this observation can be
explained by the tailored approach for the use of prasugrel
in our network with an individual risk-benefit evaluation in
patients with ACS who are undergoing PCI. This percentage
could have been lower if the 5mg dosage for patients with
an increased bleeding risk would have been reimbursed by
health insurers in the Netherlands. Nonetheless, the tailored
protocol enabled physicians to adequately triage patients to
prasugrel according to their baseline and/or bleeding risk,
thereby optimising safety and outcomes, as demonstrated
by the present low ischaemic and low bleeding event rates.
Currently, prasugrel and ticagrelor are the recommended
first-line agents in patients with ACS. We cannot reliably
establish which drug is superior over the other on the basis
of the current data [15]. For example, both agents are simi-
larly effective during the first year after MI [16] and based
on a recent meta-analysis of observational and randomised
studies totalling 21,360 patients, prasugrel appeared to be
equivalent or superior to ticagrelor in patients with ACS
who are undergoing PCI at 1-month follow-up [17].
Our findings should be considered in the context of the
following potential limitations. Inherent for all single-arm
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registry data, final efficacy and safety versus other strategies
cannot be claimed. A follow-up rate of 97.7% at one month
and 91.3% at one year represents substantial completeness
of our data. Yet is unlikely that we missed any deaths (or
potential major bleeding events leading to death) through
confirmation of municipal civil registries. Even though we
may have missed additional endpoints, we believe this may
not considerably impact the overall conclusions of our find-
ings.
Nonetheless, our data provide an objective snapshot of
the use of prasugrel in daily practice where patients are
selected on known increased bleeding characteristics, af-
fording valuable insights into treatment effectiveness and
generalisability [18]. The adherence rate of 81% at dis-
charge, the potential prasugrel cohort on target therapy as
described in the results section, was based only on prescrip-
tion data and follow-up, as well as on patient interviews at
the outpatient clinics of the enrolling sites. Unfortunately,
the design of the study did not allow us to collect informa-
tion regarding reasons for discontinuation, interruption or
disruption of prasugrel [19]. Furthermore, we did not col-
lect information regarding treatment decisions such as the
specific reasoning for initially selecting thienopyridine or
switching to thienopyridine in-hospital. Nor did we collect
any information regarding specific timings such as the exact
time of thienopyridine loading or time from loading dose
to starting angiography/PCI.
Conclusions
The CCR study shows that with the tailored antiplatelet
therapy protocol in PCI-treated ACS patients in our re-
gion patients discharged on prasugrel are predominantly
younger with less clinical comorbidities and/or presented
with STEMI compared with the patients discharged on
clopidogrel. This tailored approach resulted in low rates
of ischaemic events, including overall mortality, and no ex-
cess rates of major bleeding events for patients on prasugrel
in routine practice up to one year post PCI compared with
earlier randomised findings and observational data.
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Participating centres
Albert Schweitzer Ziekenhuis, Dordrecht; Beatrix Zieken-
huis, Gorinchem; Erasmus Medisch Centrum, Rotterdam;
Havenziekenhuis, Rotterdam; IJsselland Ziekenhuis, Rot-
terdam; Ikazia Ziekenhuis, Rotterdam; Maasstad Zieken-
huis, Rotterdam; Ruwaard van Putten Ziekenhuis, Spij-
kenisse; Sint Franciscus Gasthuis, Rotterdam; Van Weel-
Bethesda Ziekenhuis, Dirksland; and Vlietland Ziekenhuis,
Schiedam. All centres are located in the Netherlands.
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